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determinations ranged between 178 and 245 pg/mL, serum
calcium concentrations were between 10.1 and 10.6 mg/dL, and
serum phosphorus levels ranged from 4.0 to 4.8 mg/dL.
The serum PTH levels again rose three years ago to 334 and
467 pg/mL on two consecutive quarterly determinations despite
continued good control of her serum phosphorus levels. The
dose of calcitriol was raised in increments to 1.5 mg thrice
weekly over the next six to eight weeks, but the serum calcium
level increased to 11.3 mg/dL. After reducing the dose of cal-
cium carbonate from three tablets to two tablets with meals,
the serum calcium level fell to 10.7 mg/dL, but the serum
phosphorus level rose above 6.0 mg/dL and remained elevated.
When the dose of calcium carbonate was restored to three
tablets with meals, the serum calcium levels again increased,
ranging from 11.3 to 11.6 mg/dL on several weekly determina-
tions. The dose of calcitriol was then lowered to 1.0 mg threeCASE PRESENTATION
times per week. Her serum calcium levels remain between 10.7A 28-year-old white woman with end-stage renal disease due
and 11.2 mg/dL, and serum phosphorus levels range from 4.7to medullary cystic disease began treatment with hemodialysis
and 5.4 mg/dL on this therapeutic regimen. The serum PTHwhen she was 10 years old. Two years later she received a
levels continue to be elevated; recent values were 372 and 438cadaveric kidney transplant, but her clinical course was compli-
pg/mL. Several attempts at increasing the dose of calcitriol tocated by multiple episodes of rejection that resulted in graft
further lower her serum PTH levels have resulted in episodesfailure after 28 months. She resumed hemodialysis and has
of mild hypercalcemia.remained on this treatment ever since. She is currently treated
for 3.5 hours thrice weekly with a 1.8 m2 polysulfone dialyzer,
a dialysate calcium concentration of 2.5 mEq/L, and a dialysate DISCUSSIONpotassium concentration of 2 mEq/L. Mid-week pre-dialysis
BUN and creatinine are 48 mg/dL and 13.6 mg/dL, respectively. Dr. William G. Goodman (Division of Nephrology,
Her serum albumin is 4.2 g/dL, and she weighs 49 kg. A recent UCLA Medical Center; and Professor of Medicine, UCLA
Kt/V was 1.61. She takes a multivitamin preparation and three School of Medicine, Los Angeles, California, USA): This
500 mg calcium carbonate tablets with meals as a phosphate- case highlights several of the difficulties commonly en-
binding agent.
countered in managing secondary hyperparathyroidismFive years ago, calcitriol therapy was initiated because her
due to end-stage renal disease. Hyperphosphatemia andserum parathyroid hormone (PTH) levels, as measured by a
hypercalcemia are recurrent problems in many patientsdouble-antibody immunoradiometric assay, had risen to 586
pg/mL. Over the next 12 months, the serum PTH levels de- [1–4]. Hyperphosphatemia is often attributed to inade-
clined to 210 pg/mL during treatment with thrice-weekly intra- quate compliance with dietary guidelines and/or to devia-
venous doses of 2.0 mg of calcitriol. The dose of calcitriol was tions from prescribed phosphate-binding regimens, but
subsequently reduced to 0.25 mg three times per week for
it also occurs in compliant individuals with severe sec-maintenance therapy. Four years ago, her quarterly serum PTH
ondary hyperparathyroidism in whom phosphorus efflux
from bone is markedly elevated because of very high rates
Key words: PTH, hypercalcemia, hyperphosphatemia, chronic renal of osteoclastic bone resorption. Hypercalcemia com-
failure, vitamin D, calcitriol, calcimimetic agents. monly results from the use of large doses of calcium car-
bonate or calcium acetate as phosphate-binding agents orThe Nephrology Forum is funded in part by grants from Amgen Incor-
porated; Merck & Co., Incorporated; and Dialysis Clinic, Incorporated. from inappropriately high concentrations of calcium in
dialysis solutions [4, 5]. Hypercalcemia also can compli-Ó 2001 by the International Society of Nephrology
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cate treatment with vitamin D sterols [6]. These distur- of hypocalcemia [17]. They also disrupt the normal inhib-
itory action of vitamin D on pre-pro-PTH gene transcrip-bances in turn can cause soft tissue and vascular calcifi-
cations. Further, these alterations might contribute to the tion and diminish the level of VDR expression in various
tissues, rendering them less responsive to the actions ofhigh prevalence of cardiovascular disease and reduced
lifespan in patients with end-stage renal disease [7, 8]. 1,25-dihydroxyvitamin D and other vitamin D sterols [10,
18, 19]. Because vitamin D sterols exert antiproliferativeHyperphosphatemia and hypercalcemia frequently pre-
clude the use of 1,25-dihydroxyvitamin D or calcitriol to actions in a variety of cell types, low levels of 1,25-dihy-
droxyvitamin D in serum and decreases in VDR expres-lower serum PTH levels in patients with biochemical
evidence of secondary hyperparathyroidism, thereby com- sion in target tissues establish an environment conducive
to parathyroid cell proliferation and parathyroid glandpromising an effective therapeutic intervention [6]. In to-
day’s discussion, I will review several recent developments enlargement in patients with end-stage renal disease [20].
Traditional approaches to the management of second-that increase the range of therapeutic options available
to nephrologists for managing secondary hyperparathy- ary hyperparathyroidism generally address three critical
components: (1) prevention of phosphate retention androidism in patients with end-stage renal disease. Some of
these advances may permit clinicians to more effectively hyperphosphatemia; (2) maintenance of normal concen-
trations of calcium in serum; and (3) the judicious usecontrol excess PTH secretion with fewer adverse conse-
quences in patients requiring long-term dialysis. of 1,25-dihydroxyvitamin D (Fig. 1). Unfortunately, ther-
apeutic interventions designed to address these issuesThe pathogenesis of secondary hyperparathyroidism
in chronic renal failure is multifactorial, and the topic have potentially serious adverse clinical consequences.
has been reviewed in detail elsewhere [2]. Contributing
Control of serum phosphorus levelsfactors include disturbances in the regulation of PTH
secretion by parathyroid cells, alterations in the control Phosphorus retention and hyperphosphatemia can ag-
gravate the severity of secondary hyperparathyroidismof pre-pro-PTH gene transcription and PTH synthesis,
disorders of cell cycle regulation that lead to parathyroid and abrogate calcitriol’s ability to lower serum PTH lev-
els in patients with secondary hyperparathyroidism duecell proliferation and parathyroid gland hyperplasia, and
changes in the intracellular processing and peripheral to end-stage renal disease [21, 22]. As such, adequate
control of serum phosphorus levels is a cornerstone ofmetabolism of PTH [2]. Reductions in vitamin D recep-
tor (VDR) expression and in calcium-sensing receptor successful clinical management. Until the early 1980s,
aluminum hydroxide was the most widely used phosphate-(CaSR) expression in parathyroid tissue also play a role
[9, 10]. Collectively, these abnormalities yield excess binding agent in patients with chronic renal failure. Al-
though highly effective, the ingestion of large amountsPTH secretion in many patients with end-stage renal
disease. of aluminum hydroxide over many months or years led
to aluminum accumulation in bone and other tissues [23].Certain disturbances in mineral metabolism such as
hypocalcemia, hyperphosphatemia, and impaired renal When it was recognized that aluminum absorption from
the gastrointestinal tract could cause aluminum-related1,25-dihydroxyvitamin D synthesis are crucial determi-
nants of excess PTH secretion in patients with chronic bone disease and other syndromes of aluminum toxicity,
calcium-containing compounds such as calcium carbon-renal failure [2]. Therapeutic interventions designed to
control or reverse excess PTH secretion in patients with ate and calcium acetate became widely utilized for con-
trolling phosphate retention and hyperphosphatemia insecondary hyperparathyroidism are directed toward these
specific abnormalities (Fig. 1). Each disturbance modifies patients undergoing chronic dialysis [4, 24, 25].
The long-term consequences of this seminal changePTH secretion by one or more mechanisms. Hypocal-
cemia not only stimulates PTH release from the parathy- in the clinical management of patients with chronic renal
failure remain unclear. Quite large oral doses of calciumroid glands by inactivating the CaSR located within the
membrane of parathyroid cells but also increases the are required to effectively diminish intestinal phosphorus
absorption in patients with end-stage renal disease, andrate of pre-pro-PTH gene transcription [11, 12]. Hyper-
phosphatemia appears to facilitate the development of the daily amount of elemental calcium ingested typically
exceeds the 1500 mg recommended for persons withparathyroid gland hyperplasia, and high ambient phos-
phorus levels might influence post-transcriptional events normal renal function. Indeed, the intake of elemental
calcium can be as much as 5 to 8 g/day. Although thethat increase PTH messenger ribonucleic acid (mRNA)
translation and increase PTH synthesis [13–16]. Reduc- active vitamin D-dependent component of intestinal cal-
cium absorption is reduced in patients with renal failure,tions in renal 1,25-dihydroxyvitamin D production and
the ensuing low serum 1,25-dihydroxyvitamin D levels passive, or inactive, intestinal calcium transport is unreg-
ulated, and it increases as a function of the amount ofadversely affect a variety of tissues in chronic renal fail-
ure. These alterations partly account for reductions in calcium ingested [26]. Thus, episodes of hypercalcemia
are not uncommon in dialysis patients who use eitherintestinal calcium absorption and for the development
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Fig. 1. Traditional interventions designed to
prevent and control excess parathyroid hor-
mone (PTH) secretion in patients with chronic
renal failure. VDR is vitamin D receptor.
calcium carbonate or calcium acetate as phosphate-bind- undergoing dialysis who have radiographic evidence of
progressive vascular calcification [32–34]. More trou-ing agents, because these patients’ ability to excrete cal-
cium in the urine is severely compromised or completely bling, however, is the finding of coronary artery calcifica-
tion, as detected by electron beam computed tomogra-absent [27]. Hypercalcemia develops in as many as 50%
of dialysis patients given calcium carbonate to control phy, in a large proportion of young adult patients treated
with dialysis [8]. Coronary calcification is distinctly un-serum phosphorus levels [28]. The concurrent adminis-
tration of 1,25-dihydroxyvitamin D to treat secondary common in persons of the same age with normal renal
function [8]. Serum phosphorus levels and values for thehyperparathyroidism further increases the risk of hyper-
calcemia in such patients [6, 27]. calcium-phosphorus ion product were higher in patients
with coronary calcification, and these patients had beenThe ultimate fate of calcium entering the extracellular
fluid from the gastrointestinal tract or from dialysis solu- treated with dialysis much longer than had those without
evidence of coronary artery calcification [8]. Such find-tions in patients with little or no residual renal function
is not known. It is quite likely that total-body calcium ings are of interest because elevated serum phosphorus
levels have been reported to be an independent riskbalance is markedly positive in patients with end-stage
renal disease who regularly ingest large amounts of cal- factor for death in the end-stage renal disease population
in the United States (Fig. 2) [7]. Although coronary ar-cium, but this speculation has not been adequately docu-
mented because metabolic balance studies are extremely tery calcification might simply reflect the higher preva-
lence of atherosclerotic cardiovascular disease in patientsdifficult to perform in patients receiving dialysis. Never-
theless, serum calcium concentrations decline when cal- with end-stage renal disease, the daily intake of elemen-
tal calcium was nearly twofold greater in young adultcium-containing, phosphate-binding medications are
withdrawn for short periods; thus, a portion of the cal- dialysis patients with coronary calcification than in those
without this abnormality [8]. Additional studies arecium ingested clearly gains entry into the extracellular
fluid [29, 30]. Dialysis patients with adynamic renal os- needed to determine the relationship between distur-
bances in mineral metabolism and the development ofteodystrophy are more likely to be receiving calcium-
containing medications than are patients with high-turn- vascular calcification in patients with chronic renal fail-
ure. These preliminary results suggest, however, thatover skeletal lesions. This finding suggests that calcium
intake can influence serum PTH levels and the rate of disturbances in mineral metabolism and the interven-
tions designed to manage them inadvertently contributebone remodeling in patients with end-stage renal disease
[31]. Concern has grown, therefore, that the administra- to the development and progression of vascular disease
in patients undergoing long-term dialysis.tion of large quantities of calcium to patients with chronic
renal failure will aggravate the development of soft tissue In light of these observations, it would be prudent for
us to avoid giving excess amounts of calcium to patientsand vascular calcification [32].
Exogenous calcium loading has been implicated in the with end-stage renal disease if hypocalcemia can be
avoided and if serum phosphorus levels can be ade-pathogenesis of the syndrome of calciphylaxis in patients
Nephrology Forum: Treating secondary hyperparathyroidism1190
patients with end-stage renal disease [29, 38]. In a long-
term study, LDL cholesterol levels decreased by approxi-
mately 30%, whereas HDL cholesterol levels rose by 18%
after 46 weeks of treatment [37]. Although interventions
aimed at lowering serum lipid levels have not yet been
shown to improve cardiovascular outcomes in patients
undergoing long-term dialysis, the cholesterol-lowering
properties of sevelamer might favorably modify an estab-
lished risk factor for cardiovascular disease in a popula-
tion at risk for developing cardiovascular disease [39].
The use of sevelamer might allow us to control serum
phosphorus levels while reducing the amount of exoge-
nous calcium given to patients undergoing dialysis. Al-
though the results of short-term studies have been en-
couraging, the consequences of the long-term use of
Fig. 2. Relative mortality risk according to quintiles for serum phos- sevelamer for many months or several years in patientsphorus concentrations in patients with end-stage renal disease treated
with end-stage renal disease are not known. Ongoingwith dialysis. (Adapted from [7]).
vigilance for potential untoward effects during the sus-
tained use of this agent is warranted, considering adverse
experiences with compounds such as aluminum hydrox-
quately controlled using alternative phosphate-binding ide and calcium carbonate in this patient population.
regimens. Sevelamer hydrochloride, a hydrogel of cross- Other compounds that do not contain calcium or alu-
linked poly-allylamine hydrochloride (RenaGelR), is a minum also are being evaluated as potential phosphate-
theoretically attractive option for managing serum phos- binding agents [40, 41]. Lanthanum carbonate is an effec-
phorus levels in dialysis patients because it does not tive phosphate-binding agent in experimental animals,
contain calcium or aluminum [29]. This synthetic poly- and it is currently being evaluated in phase III clinical
mer was specifically designed to bind phosphorus within trials [41]. Various iron salts including iron citrate, iron
the lumen of the gastrointestinal tract and thus prevent chloride, and iron ammonium citrate as well as other,
its absorption. When given to normal volunteers, seve- more complex, iron compounds such as iron dextran also
lamer decreases phosphorus excretion in the urine; this have been studied [40]. The clinical utility of these agents
change is consistent with a reduction in intestinal phos- as phosphate-binding medications in patients with end-
phorus absorption [35]. In controlled studies of patients stage renal disease ultimately will be determined by their
undergoing hemodialysis for end-stage renal disease, the efficacy in controlling serum phosphorus levels, by the
administration of sevelamer for eight weeks was as effec- ability of patients to comply with the dosage regimens
tive as either calcium carbonate or calcium acetate in required, by the absence of untoward side effects, and
controlling serum phosphorus levels [36]. In a larger by the lack of toxicity with long-term exposure.
multicenter study of 84 hemodialysis patients, sevelamer
Prevention of hypocalcemiaand calcium acetate were similarly effective in lowering
serum phosphorus levels during an eight-week dose esca- Mild hypocalcemia often develops in patients with
lation trial [30]. Episodes of hypercalcemia, as defined moderate to advanced renal failure, and it was a common
by serum calcium concentrations exceeding 11.0 mg/dL, finding in patients starting dialysis when aluminum hy-
occurred in 22% of patients receiving calcium acetate droxide was used as the primary agent for controlling
but in only 5% of those given sevelamer. Serum calcium hyperphosphatemia in progressive renal disease [42].
levels during treatment with sevelamer have generally Decreases in intestinal calcium absorption largely ac-
remained unchanged in short-term studies, whereas values count for this finding, which results from impaired renal
rose an average of 0.3 to 0.4 mg/dL during a 46-week trial calcitriol production and reductions in the serum levels
in 192 adult hemodialysis patients [37]. The mechanism of 1,25-dihydroxyvitamin D [42]. Oral calcium supple-
responsible for this modest rise is unclear, but a decrease ments or small doses of oral calcitriol frequently were
in the amount of unbound dietary phosphorus available used to restore serum calcium levels to normal. Recent
to form insoluble complexes with calcium in the lumen reports indicate, however, that serum calcium levels are
of the intestine during the administration of sevelamer normal in many patients when chronic dialysis is begun
might leave relatively more calcium available for trans- and that serum PTH levels are either normal or only
port across the intestinal epithelium [37]. minimally elevated despite no previous treatment with
Interestingly, serum levels of total cholesterol and vitamin D sterols [43]. The use of large oral doses of
calcium as phosphate-binding agents probably explainsLDL cholesterol decline during sevelamer treatment in
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these findings, but currently no data directly address this rum PTH levels in patients with biochemical or histo-
issue. pathologic evidence of secondary hyperparathyroidism
As I said, hypocalcemia provokes the release of PTH [6, 49, 51]. Although this approach generally is effective,
by reducing the level of activation of the CaSR in the serum calcium levels frequently rise during treatment,
membrane of the parathyroid cell. Serum PTH levels rise particularly in patients ingesting large amounts of calcium,
promptly, and values remain elevated if hypocalcemia and the development of hypercalcemia mandates tempo-
persists [44]. Reductions in ambient calcium levels also rary interruptions in therapy and/or reductions in dose
diminish the effect of calcium to negatively regulate (that [6]. Because calcitriol also facilitates the absorption of
is, inhibit) pre-pro-PTH gene transcription through a phosphorus from the gastrointestinal tract, serum phos-
calcium-response element located approximately 3.6 ki- phorus levels can increase and hyperphosphatemia often
lobases upstream from the gene for pre-pro-PTH [12]. develops. As I said earlier, the occurrence of hypercalce-
In addition to short-term changes in PTH release and mia or hyperphosphatemia, or the development of ele-
gene transcription, sustained decreases in serum calcium vated values for the calcium-phosphorus ion product,
concentrations lead to parathyroid gland hyperplasia necessitates withholding calcitriol or reducing its dose
[20]. The prevention of hypocalcemia is essential if we to minimize the risk of soft tissue calcification.
are to avoid this complication in patients with end-stage A major objective of the treatment of secondary hy-
renal disease. perparathyroidism with vitamin D sterols is the suppres-
When calcitriol was introduced as an oral preparation sion of pre-pro-PTH gene transcription and PTH secre-
for the treatment of secondary hyperparathyroidism in tion without provoking increases in intestinal calcium
patients with end-stage renal disease, its ability to en- and phosphorus absorption, which lead to hypercalcemia
hance intestinal calcium absorption was viewed favor- and hyperphosphatemia. Unfortunately, the therapeutic
ably because serum calcium levels in many untreated index for calcitriol is quite narrow, and the doses re-
patients with secondary hyperparathyroidism were low quired to adequately lower serum PTH levels in many
[45]. The resolution of hypocalcemia during calcitriol patients with established secondary hyperparathyroid-
therapy removed a potent stimulus for PTH secretion ism frequently produce unacceptably high serum levels
and contributed substantially to subsequent reductions of calcium and phosphorus. As a result, considerable
in serum PTH levels. This response was distinct from interest has been directed toward the identification and
vitamin D sterols’ ability to diminish pre-pro-PTH gene clinical development of vitamin D sterols that diminish
transcription. The effect of calcitriol on intestinal calcium PTH secretion without promoting intestinal calcium ab-
transport is dose-dependent, however, and the develop- sorption [52]. Such compounds would allow greater flex-
ment of hypercalcemia limits the total amount that can
ibility in dosing that would lead to control of excess PTHbe given [45–47]. In adult patients with end-stage renal
secretion in patients with secondary hyperparathyroid-disease, hypercalcemia frequently develops when daily
ism and would provide a larger margin of safety duringoral doses of calcitriol exceed 0.5 mg.
treatment. Several vitamin D sterols that possess some ofWith the introduction of the parenteral form of 1,25-
these features are now available for clinical use (Table 1).dihydroxyvitamin D, it became more convenient for cli-
One of the first vitamin D analogues shown to diminishnicians to treat patients who had secondary hyperpara-
PTH secretion but with limited effects on intestinal cal-thyroidism by administering calcitriol thrice weekly dur-
cium transport was 22-oxacalcitriol, or 22-oxa-1,25-dihy-ing hemodialysis procedures [48, 49]. Interestingly, larger
droxyvitamin D3 (OCT). The basic structure of the vita-cumulative weekly doses of calcitriol could be given with-
min D3 molecule has been modified by substitution ofout inducing hypercalcemia when a thrice-weekly paren-
an oxygen atom for the carbon at the 22-position of theteral dosing schedule was used rather than daily oral
side chain (Fig. 3). Studies in dispersed parathyroid cellsdoses. The mechanism that accounts for this difference
in tissue culture demonstrated that OCT was as effectiveis not known, but variations in pharmacokinetics be-
as calcitriol in decreasing PTH secretion in vitro [53],tween the intravenous and oral routes of calcitriol admin-
and the administration of single doses of OCT to ratsistration might be responsible [50]. The local effect of
markedly lowered the levels of mRNA expression for1,25-dihydroxyvitamin D, that is, enhancing the move-
pre-pro-PTH in the parathyroid glands [53]. The admin-ment of calcium across the intestinal epithelium (a phe-
istration of OCT for 60 weeks to subtotally nephrecto-nomenon known as “transcaltachia”), also might contrib-
mized dogs with secondary hyperparathyroidism con-ute to the rise in serum calcium concentrations during
trolled serum PTH levels and improved the histologicoral calcitriol therapy.
changes of secondary hyperparathyroidism in bone [54].
Treatment of secondary hyperparathyroidism with But episodes of hypercalcemia and hyperphosphatemia
vitamin D sterols occurred in animals receiving OCT, whereas earlier stud-
ies in the rat suggested that systemic administration ofSince the mid-1980s, thrice-weekly doses of intrave-
nous calcitriol have been widely employed to lower se- OCT did not increase serum calcium concentrations.
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Table 1. Vitamin D analogues: Alternatives to calcitriol
Generic name Chemical name Trade name
22-Oxacalcitriol (OCT) 22-oxa-1,25-dihydroxyvitamin D3 Maxacalcitola
Paricalcitol 19-nor-1,25-dihydroxyvitamin D2 Zemplar
Doxercalciferol 1-alpha-hydroxyvitamin D2 Hectoral
Alfacalcidol 1-alpha-hydroxyvitamin D3 One-Alpha
a Not yet available for clinical use
Fig. 3. The molecular structures of 1a,25-dihy-
droxyvitamin D3 (calcitriol); 22-oxa-1a,25-dihy-
droxyvitamin D3 (22-oxacalcitriol or OCT);
1a,hydroxyvitamin D2 (doxercalciferol); and
19-nor-1a,25-dihydroxyvitamin D2 (paricalcitol).
Whether these differences reflect variations in the bio- that normally extends beyond the A ring of the vitamin
D molecule (Fig. 3). Intraperitoneal administration oflogic response to OCT among species remains unclear.
In the rat, reductions in the affinity of OCT for the paricalcitol reduces serum PTH levels but produces little
or no change in blood ionized calcium concentrations invitamin D binding protein appear to shorten the half-
life of the compound in serum, thus reducing the impact subtotally nephrectomized rats with secondary hyper-
parathyroidism [56]. When compared with calcitriol,of OCT administration on intestinal calcium transport.
Tissue-specific differences in the catabolism of OCT by much larger doses of paricalcitol are required to raise
serum calcium and phosphorus levels in rats with renalintestinal cells also might influence its biologic actions
[55]. Clinical trials using 22-oxacalcitriol for the treat- failure. Yet the release of PTH from bovine parathyroid
cells in tissue culture is reduced to a similar degree byment of secondary hyperparathyroidism in patients un-
dergoing hemodialysis are currently in progress. equimolar concentrations of paricalcitol and calcitriol [57].
Paricalcitol appears to be less effective than calcitriol inParicalcitol, 19-nor-1,25-dihydroxyvitamin D2, is a vi-
tamin D2 analogue currently available in the United States upregulating intestinal VDR expression, and this differ-
ence perhaps accounts for smaller increases in serum cal-for the treatment of secondary hyperparathyroidism in
patients with end-stage renal disease. This compound cium concentrations in animals given intraperitoneal doses
of paricalcitol compared with those given calcitriol [58].contains the side chain that characterizes vitamin D2, but
it lacks a double-bond structure at the 19-carbon position The biochemical response to paricalcitol therapy in
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Fig. 4. Serum total calcium and phosphorus
concentrations during 12 weeks of treatment
with paricalcitol (solid lines) or placebo (dashed
lines) in 78 hemodialysis patients with second-
ary hyperparathyroidism. Forty patients re-
ceived paricalcitol and 38 were given placebo.
Values are means 6 SEM. (From [59]).
patients with secondary hyperparathyroidism due to end- constant serum levels of calcium and phosphorus during
the 12 weeks of paricalcitol therapy suggest that serumstage renal disease was examined in a placebo-controlled
clinical trial lasting 12 weeks in 78 hemodialysis patients PTH levels can be effectively lowered in many patients
with relatively few vitamin D-induced episodes of hyper-[59]. The initial dose of paricalcitol was 0.4 mg/kg body
weight, or 2.8 mg/70 kg, given intravenously during hemo- calcemia and hyperphosphatemia. Paricalcitol is avail-
able for parenteral administration to patients undergoingdialysis three times per week. Serum calcium, phospho-
rus, and PTH levels were measured weekly. Doses of hemodialysis. An oral preparation is not yet available,
and little is known about the use of intraperitoneal dosesparicalcitol were increased at two-week intervals if serum
calcium and phosphorus levels and the calcium-phospho- of paricalcitol in treating secondary hyperparathyroidism
in patients undergoing peritoneal dialysis.rus ion product remained within pre-established safety
guidelines, or if serum PTH values had not fallen by One-a-hydroxyvitamin D2, or doxercalciferol, is an-
other vitamin D2 compound available for use in the treat-30% from pre-treatment levels. Pre-treatment serum
PTH levels averaged 785 6 66 pg/mL (mean 6 SEM) ment of secondary hyperparathyroidism in patients with
end-stage renal disease. Doxercalciferol contains the vi-in 40 patients given paricalcitol and 745 6 52 pg/mL
in 38 given placebo; these values are consistent with tamin D2 side chain, and it has an a-hydroxyl group
located at the 1-carbon position (Fig. 3). In this regard,moderate to severe secondary hyperparathyroidism. Se-
rum PTH levels were unchanged during 12 weeks of 1-a-hydroxyvitamin D2 is analogous to 1-a-hydroxyvita-
min D3, or alfacalcidol, which is used widely in Europetreatment in patients given placebo but fell by more
than 50% from pre-treatment levels in patients receiving and Japan. Alfacalcidol undergoes 25-hydroxylation in
the liver to form the biologically more active metaboliteparicalcitol. Despite a progressive rise in the average
weekly dose of paricalcitol during the first eight weeks 1,25-dihydroxyvitamin D3. Since doxercalciferol and
alfacalcidol already have an a-hydroxyl group at theof therapy, serum calcium and phosphorus levels did not
change from pre-treatment levels during the 12-week 1-carbon position, they do not need to undergo biochem-
ical activation in the kidney; this is a distinct advantagetreatment interval (Fig. 4). Seven patients manifested
eight episodes of hypercalcemia, most of which occurred in patients with chronic renal failure. Nevertheless, both
compounds are considered pro-hormones, as each mustafter serum PTH levels had decreased markedly during
treatment, often to values less than 100 pg/mL [59]. undergo hydroxylation at the 25-carbon position to at-
tain full biologic activity.Such findings indicate that paricalcitol can effectively
lower serum PTH levels without substantially raising It has been known for many years that the actions of
doxercalciferol in the rat are similar to those of 1-a-serum calcium or phosphorus concentrations in patients
with moderate to severe secondary hyperparathyroid- hydroxyvitamin D3 with respect to the healing of rachitic
bone lesions, the mobilization of calcium from bone, andism. The response of patients treated with paricalcitol
was not compared to that of a separate group of patients the enhancement of intestinal calcium absorption [60].
Much higher doses of doxercalciferol are required, how-given calcitriol, however. It therefore remains unknown
whether episodes of hypercalcemia and hyperphosphate- ever, to achieve similar biologic responses [61]. In studies
of older women with osteoporosis, daily oral doses asmia occur less often in patients treated with paricalcitol
than in patients given calcitriol. Nevertheless, the fairly high as 5 mg could be administered before hypercalciuria
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developed [62]. Because doxercalciferol can be activated
in the liver only after absorption from the gastrointesti-
nal tract, high concentrations of the more potent sterol
1,25-dihydoxyvitamin D2 are not present within the intes-
tinal lumen to modify transepithelial calcium movement.
The unavailability of 1,25-dihydroxyvitamin D2 might
account for smaller net increases in intestinal calcium
absorption during the oral administration of 1-a-hydroxy-
vitamin D2.
Doxercalciferol effectively lowers serum PTH levels
in hemodialysis patients with established secondary hy-
perparathyroidism. During 12 weeks of treatment with
initial oral doses of either 4.0 mg/day or 4.0 mg thrice
weekly after hemodialysis, serum PTH levels declined
from pre-treatment values of 672 6 70 pg/mL to 289 6
36 pg/mL in 24 patients [63]. Serum calcium levels rose Fig. 5. Plasma PTH levels expressed as a percentage of pretreatment
values in 99 hemodialysis patients with secondary hyperparathyroidismmodestly from an average of 8.8 mg/dL near the end
who were treated with doxercalciferol for 16 weeks. Patients were thenof an 8-week pre-treatment stabilization period during randomly assigned to placebo therapy ( ; N 5 51), or they continued
which no vitamin D sterols were given to 9.5 mg/dL after treatment with doxercalciferol (h, N 5 48). Plasma PTH levels rose
promptly after doxercalciferol therapy was withdrawn in placebo-12 weeks. Thirteen episodes of hypercalcemia, as defined
treated patients. Values are means 6 SEM. (Adapted from [64]).by a serum calcium concentration exceeding 10.5 mg/dL,
occurred in 10 patients. Hypercalcemia resolved prompt-
ly within three to seven days after temporary withholding
of doses of doxercalciferol. Mean serum phosphorus lev- during the final eight weeks of this clinical trial have
els did not change during treatment, and the frequency important implications regarding the use of vitamin D
of episodes of hyperphosphatemia, as defined by a serum sterols for the long-term management of patients with
phosphorus level exceeding 6.9 mg/dL, was no greater secondary hyperparathyroidism. Plasma PTH levels in-
during 12 weeks of doxercalciferol therapy than during creased promptly within one to two weeks after doxercal-
the 8-week pre-treatment interval [63]. In a larger study ciferol was withdrawn in placebo-treated patients, but
of 99 adult hemodialysis patients, doxercalciferol was values remained low in those who continued to receive
given at an initial oral dose of 10 mg thrice weekly [64]. doxercalciferol (Fig. 5). Indeed, plasma PTH levels 4
The treatment protocol comprised two phases: during an weeks after treatment with doxercalciferol was discon-
initial 16-week, open-label period, all patients received tinued did not differ from PTH levels obtained 20 weeks
doxercalciferol. At the end of the open-label treatment
earlier, before treatment was begun [64].
interval, patients were randomly assigned either to con-
Decreases in serum PTH levels during treatment oftinue therapy with doxercalciferol or to receive placebo
secondary hyperparathyroidism with vitamin D sterolsfor an additional 8-week blinded phase of the study.
generally have been thought to reflect, at least in part,Plasma PTH and serum total calcium concentrations
a reduction in parathyroid gland size [65]. The re-emer-were measured weekly. Treatment with doxercalciferol
gence of parathyroid gland hyperplasia within a four-produced prompt and substantial reductions in plasma
week interval is not likely to account for the prompt risePTH levels. Values decreased by 20% after one week
in plasma PTH levels after treatment with doxercalcif-and by 35% after two weeks from a pre-treatment mean
erol is discontinued, however. Reductions in pre-pro-of 897 6 52 pg/mL. Plasma PTH levels decreased more
PTH gene transcription and PTH synthesis, rather thangradually thereafter but continued to decline for the
decreases in parathyroid gland mass, appear to be largelyremainder of the open-label treatment interval. In 99
responsible for the decline in serum PTH levels duringpatients who received doxercalciferol for 16 weeks, PTH
treatment with doxercalciferol. As such, maintenancelevels fell by more than 60% from pre-treatment values;
therapy with doxercalciferol and other vitamin D ana-PTH values were within the pre-established therapeutic
logues might be required to achieve sustained reductionstarget range of 150 to 300 pg/mL in 83% of the patients.
in serum PTH levels in patients with secondary hyper-Serum calcium levels rose modestly during treatment
parathyroidism who respond favorably to treatment withfrom 9.0 6 0.1 to 9.8 6 0.1 mg/dL, whereas serum phos-
vitamin D sterols.phorus levels were unchanged. Episodes of hypercalce-
Overall, doxercalciferol rapidly and effectively lowersmia, defined as a serum calcium concentration above
plasma PTH levels in patients with secondary hyperpara-11.2 mg/dL, occurred at a rate of 3.5 episodes per 100
patient-months of treatment [64]. The results obtained thyroidism due to end-stage renal disease. Additional
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studies will be required to determine whether episodes
of hypercalcemia and hyperphosphatemia occur substan-
tially less frequently during treatment with doxercalcif-
erol than with calcitriol. Doxercalciferol is available in
capsule form for oral administration. A parenteral prepa-
ration has been evaluated in clinical trials and is currently
pending approval by regulatory authorities.
Calcimimetic agents
As I said earlier, the CaSR in the membrane of the
parathyroid cell modulates the minute-to-minute release
of PTH into the circulation. Thus, CaSR is the molecular
mechanism by which parathyroid tissues detect changes
in the concentration of ionized calcium in blood and
modulate PTH secretion. The structural features of the
CaSR and its role in the pathophysiology of various
Fig. 6. Blood-ionized calcium concentrations (top panel) and plasmaclinical disorders of mineral metabolism have been re- PTH levels (bottom panel) after initial doses of R-568 in 16 hemodialysis
viewed in detail elsewhere [11]. Calcimimetic agents are patients with secondary hyperparathyroidism. Values are means 6
SEM. (Adapted from [74]).small organic compounds that modify signal transduction
by the CaSR [66, 67]. They increase the level of activation
of the CaSR by extracellular calcium ions and reduce
PTH release from the parathyroid cell [68]. The time in secondary hyperparathyroidism due to chronic renal
course of the effect on PTH secretion in vivo is measured
failure. In a pilot study in a small number of hemodialysis
in minutes or hours [66]. These properties differ mark-
patients with mild secondary hyperparathyroidism, the
edly from those of the vitamin D sterols, which modify
administration of single oral doses of R-568 on two con-PTH secretion over many hours or days by reducing the
secutive days consistently lowered serum PTH levelsrate of pre-pro-PTH gene transcription and by raising
within a few hours [74]. We examined the response toserum calcium levels [18, 69].
repeated doses of R-568 in 16 hemodialysis patients withSeveral calcimimetic agents activate the calcium-sens-
moderate to severe secondary hyperparathyroidism [75].ing receptor in parathyroid cells and diminish PTH re-
Patients received single oral doses of 100 mg of R-568lease in vitro [70]. These compounds modify receptor
daily for 15 days. Plasma PTH levels, blood ionized cal-activation across a range of extracellular calcium concen-
cium concentrations, and serum total calcium levels weretrations and alter the relationship between the level of
measured at frequent and regular intervals during treat-calcium in extracellular fluid and the amount of PTH
ment. On several days during the study, we examinedreleased from the parathyroid cell. Thus, relatively less
in greater detail changes in plasma PTH levels and bloodPTH is released at any given level of extracellular cal-
ionized calcium concentrations as long as 24 hours aftercium. By directly activating the CaSR, reductions in PTH
the administration of R-568. Pre-treatment plasma PTHrelease occur without an antecedent rise in extracellular
levels averaged 599 6 105 pg/mL. The oral administra-calcium concentration. Indeed, serum calcium levels typ-
tion of R-568 produced a rapid and substantial reductionically decrease after the administration of calcimimetic
in plasma PTH levels in all patients; values decreasedcompounds to humans or experimental animals, proba-
on average by more than 75% two hours after the initialbly because of changes in renal calcium excretion and/or
dose (Fig. 6) [75]. Plasma PTH levels gradually rosealterations in calcium fluxes between bone and extracel-
thereafter but remained below pre-treatment values im-lular fluid [67, 71, 72]. These features make it possible
mediately before the administration of R-568 on theto directly lower serum PTH and calcium levels in pa-
second day of treatment. In contrast to the changes intients with hypercalcemia due to excess PTH secretion
plasma PTH, blood ionized calcium concentrations de-in whom treatment with vitamin D sterols cannot be
clined progressively throughout the day on the first dayundertaken safely.
of treatment. These responses were documented on allTreatment with the calcimimetic agent R-568 lowers
study days on which repeated measurements of plasmaserum PTH levels and reverses the histologic changes of
PTH and blood ionized calcium concentrations were ob-osteitis fibrosa in bone in rats with renal failure and
tained. Interestingly, there was no relationship betweensecondary hyperparathyroidism [67]. This compound also
the extent of the decrease in blood ionized calcium con-prevents the development of parathyroid gland hyperpla-
centration and the pre-dose plasma PTH level.sia in uremic animals [73]. Thus, calcimimetic agents repre-
sent a novel approach for controlling excess PTH secretion Plasma PTH levels, obtained immediately before daily
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alterations in the level of CaSR expression in the para-
thyroid glands do not modify the biochemical response to
calcimimetic agents in patients with chronic renal failure.
The consistency of the ability of R-568 to reduce plasma
PTH levels and to lower serum calcium concentrations
suggests that calcimimetic compounds are particularly
effective in controlling excess PTH secretion in patients
with advanced secondary hyperparathyroidism in whom
elevated serum calcium levels preclude the use of vitamin
D sterols.
Unfortunately, the bioavailability of R-568 is low, and
the metabolism of the drug is quite variable. As a result,
another calcimimetic agent with similar biologic actions
but a more consistent pharmacokinetic profile is now
being evaluated in clinical trials. Additional studies are
needed to determine how these drugs can be used safely
for long periods without producing dose-limiting reduc-
Fig. 7. Plasma PTH levels (top panel) and serum total calcium concen- tions in serum calcium concentrations and how alterna-
trations (bottom panel) during 15 days of treatment with single daily tive dosage regimens might be used to attenuate theoral doses of 100 mg of R-568 in 16 hemodialysis patients with secondary
magnitude of this change. The administration of vitaminhyperparathyroidism. Values are means 6 SEM. (Adapted from [75]).
D sterols to maintain serum calcium levels during treat-
ment with calcimimetic agents represents an additional
option. The concurrent use of vitamin D and calcimi-
doses of R-568, decreased progressively for the first nine metic agents might provide a particularly powerful
days of treatment despite a concurrent decline in total method for controlling excess PTH secretion in patients
serum calcium concentrations (Fig. 7). Overall, plasma with secondary hyperparathyroidism.
PTH levels remained below pre-treatment values for the
15-day treatment interval [75]. Therefore, R-568 could Summary
diminish PTH secretion sufficiently to overcome the Important new therapeutic agents are now available
stimulus to PTH release provided by the fall in serum for the clinical management of secondary hyperparathy-
calcium concentration. Five patients withdrew from the roidism in patients with end-stage renal disease, and oth-
study because they developed symptoms of hypocal- ers may soon be introduced. The potential benefits asso-
cemia; two asymptomatic patients were withdrawn for ciated with these advances and unresolved issues about
safety considerations because their blood ionized cal- their long-term use in patients with chronic renal failure
cium levels were less than 1.0 mmol/L. The occurrence are summarized in Table 2. These developments offer
of hypocalcemia was due, in part, to protocol guidelines clinicians a greater range of therapeutic alternatives for
that limited adjustments to the dose of R-568 and pre- the management of patients with secondary hyperpara-
cluded changes in the doses of other medications such thyroidism, and use of these agents might circumvent
as vitamin D sterols or calcium carbonate that likely some of the adverse effects associated with traditional
would have offset reductions in serum calcium levels. approaches to treatment.
Nevertheless, the results indicate that repeated doses of
a calcimimetic agent can markedly and consistently lower
QUESTIONS AND ANSWERSserum PTH levels in patients with moderate to advanced
secondary hyperparathyroidism due to end-stage renal Dr. Nicolaos E. Madias (Executive Academic Dean,
disease. Tufts University School of Medicine, Boston, Massachu-
The response to R-568 was consistent among patients setts): Can you tell us about differences in the binding
and did not vary with the biochemical severity of second- of the new vitamin D analogues to vitamin D binding
ary hyperparathyroidism [75]. Thus, plasma PTH levels proteins and vitamin D receptors and the influence of
declined in all patients given R-568, even in those with these agents on the expression of receptors for vitamin
severe disease and markedly elevated serum PTH levels. D and the calcium-sensing receptor?
Because CaSR expression is diminished in parathyroid Dr. Goodman: The binding affinity of 22-oxa-calcitriol
tissues obtained from patients with advanced disease [9], to the vitamin D binding protein in serum is considerably
lesser decreases in plasma PTH levels after doses of less than that of calcitriol [76]; this difference appears
R-568 might have been expected in such patients. The to account for the shorter half-life of 22-oxa-calcitriol in
serum and its lesser impact on intestinal calcium absorp-results of this small clinical trial suggest, however, that
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tion compared to calcitriol. Tissue-specific differences in
degradation rates also might contribute. As I mentioned
previously, paricalcitol is less effective than calcitriol in
up-regulating intestinal mRNA levels for the vitamin D
receptor (VDR), but it is as effective as calcitriol in
suppressing PTH mRNA levels in parathyroid cells.
Calcitriol, 1,25(OH)2D3, and the activated metabolite of
doxercalciferol, 1,25(OH)2D2, bind with equal affinity to
the VDR, but much larger doses of doxercalciferol are
required to raise serum calcium levels in vivo [61, 62].
Whether this disparity reflects differences between the
two vitamin D compounds on intestinal calcium fluxes
that are mediated by non-genomic actions, that is, “trans-
caltachia,” remains to be determined. There are conflict-
ing results about the role of calcitriol as a regulator of
CaSR expression, and additional work will be required
to clarify this matter.
Dr. Madias: A question about calcimimetics. In the
most severe cases of parathyroid hyperplasia with nodu-
lar transformation and possibly monoclonal cell growth,
the complement of calcium-sensing receptors is decreased.
Is there evidence that calcimimetic agents are less effec-
tive in patients with so-called “tertiary hyperparathy-
roidism” and hypercalcemia? Also, does the presence of
hyperphosphatemia modify the action of calcimimetic
agents?
Dr. Goodman: The limited available data suggest that
the severity of secondary hyperparathyroidism does not
modify the response to calcimimetic agents. The calcimi-
metic compound R-568 consistently lowered plasma
PTH levels by approximately 75% from pre-treatment
values two hours after single oral doses in 16 patients
with secondary hyperparathyroidism whose basal PTH
levels ranged from 300 to 1200 pg/mL [75]. The percent-
age decrease in plasma PTH levels did not correlate with
either the pre-dose level of PTH or the pre-dose blood
ionized calcium concentration. Thus, the biochemical se-
verity of secondary hyperparathyroidism, as judged by
basal plasma PTH levels, did not influence the response
to this therapeutic agent. Despite these findings, none
of the individuals given R-568 had true “tertiary hyper-
parathyroidism,” as stringently defined by the need for
parathyroidectomy in the months immediately following
evaluation. It is not known, therefore, whether calcium-
sensing receptor expression was indeed reduced in these
individuals. Although less well studied, the response to
calcimimetics also does not seem to be affected by the
level of phosphorus in blood.
Dr. Madias: You mentioned that hypocalcemia can
occur during treatment with calcimimetics. Do these
agents also affect serum phosphorus levels?
Dr. Goodman: In the study of the calcimimetic agent
R-568 that I mentioned earlier, serum phosphorus levels
did not change from pre-dose values on two separate
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to 24 hours after daily oral doses [75]. Serum phosphorus consequences associated with their long-term use were
recognized. Unfortunately, adequate consideration mightdeterminations were not done, however, at regular inter-
vals during this 24-day study. Preliminary data from an not have been given to the possibility of untoward effects
from the administration of very large oral doses of calciumongoing clinical trial using AMG-073, another calcimi-
metic agent, indicate that after six months of follow-up, to individuals with little or no renal function. It was ex-
pected that much of the calcium ingested would formserum phosphorus levels and serum PTH levels both
were lower than pre-treatment values in those given the poorly soluble complexes with phosphorus in the intesti-
nal lumen, leaving relatively little unbound calcium avail-calcimimetic compound than in controls who received a
placebo (abstract; Lindberg et al, J Am Soc Nephrol able for absorption. Decreases in vitamin D-dependent
intestinal calcium absorption due to impaired renal calci-11:578, 2000). A decrease in the amount of phosphorus
released from bone during skeletal remodeling is one triol production also might have been thought to provide
some degree of protection against excess calcium entrypossible explanation for this finding, but additional stud-
ies are needed to clarify this issue. into the extracellular fluid. But the frequency of episodes
of hypercalcemia in dialysis patients given large oralDr. David Lee (Division of Nephrology, Sepulveda
VA Hospital, Sepulveda, California): The calcium-sens- doses of calcium indicates that such considerations are
insufficient to avoid excess calcium absorption.ing receptor is a member of the G-protein-coupled recep-
tor superfamily. These hormone receptors are activated The limited use of aluminum-containing compounds
over several months is unlikely to cause substantial alu-by nanomolar quantities of their respective agonists. Yet
the calcium-sensing receptor is not activated in an ocean minum accumulation in bone and other tissues if agents
known to increase intestinal aluminum absorption, suchof calcium in view of the fact that the calcium concentra-
tion in extracellular fluid is measured in millimoles per as citrate, are not given concurrently. Aluminum-con-
taining phosphate binders represent a viable short-termliter. Instead, it is activated by very slight changes in
the concentration of extracellular calcium. What is the alternative for managing phosphorus retention in pa-
tients who develop hypercalcemia when taking calciummolecular explanation for this rather unusual form of
agonist-receptor interaction? carbonate or calcium acetate and in those for whom the
tolerated dose of sevelamer does not provide adequateDr. Goodman: Activation of this family of receptors
by ligands that bind to the extracellular domain typically control of serum phosphorus levels.
Dr. Madias: Regarding your study of young personsresult in transient increases in cytosolic calcium concen-
tration because of the mobilization of calcium from the with coronary calcification, were other cardiovascular
risk factors present in these individuals, such as elevatedendoplasmic reticulum. The change in intracellular cal-
cium concentration is indeed measured in micromoles serum levels of homocysteine or lipoprotein(a)? Did any
of these patients have clinical evidence of coronary arteryper liter, but the change is a response to receptor activa-
tion, not a receptor-activating event. Similar transient disease?
Dr. Goodman: We were unable to obtain fasting lipo-increases in cytosolic calcium occur with activation of the
CaSR. In this case, however, the relevant extracellular protein profiles on these individuals, and the serum levels
of lipoprotein(a) and homocysteine were not measured.ligand is calcium rather than a peptide hormone or a
glycoprotein. To serve as a viable mechanism for de- None of the patients had clinical manifestations of coro-
nary artery disease, but six had electrocardiographic ab-tecting changes in extracellular calcium concentration,
the affinity of regions within the extracellular domain normalities distinct from those that could be attributed
to hypertension. Five patients had ischemic changes onof the CaSR that are responsible for interacting with
extracellular calcium ions must fall within the appro- electrocardiogram, and one had first-degree atrioventric-
ular block. Mitral valve calcification was detected bypriate physiologic range. These levels are much higher
in the extracellular compartment than in the intracellular echocardiography in two patients, and one of them has
since undergone surgery to replace both the mitral andcompartment.
Dr. Gabriel Danovitch (Division of Nephrology, aortic valves. A calcified atheromatous plaque near the
ostium of the right coronary artery was identified byUniversity of California, Los Angeles, California): Bear-
ing in mind what you told us about the impact of calcium- echocardiography in one other patient.
Dr. Alan Wilkinson (Division of Nephrology, Uni-containing phosphate binders on coronary calcification,
do you think that the nephrology community abandoned versity of California, Los Angeles): One contender for
interrupting the syndrome of secondary hyperparathy-the use of aluminum-based binders too quickly? Is there
still a place for aluminum-containing, phosphate-binding roidism would be antagonists of the parathyroid hor-
mone receptor. Have such agents been evaluated, oragents in clinical practice?
Dr. Goodman: It was certainly appropriate to mark- have attempts to produce them been unsuccessful? If
they have been used, has the clinical consequence beenedly curtail the use of aluminum-containing compounds
in patients with end-stage renal disease when the adverse unacceptable?
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Dr. Goodman: I am not aware of small molecules or striking degree of tissue hyperplasia. In addition, bone and
growth plate cartilage exhibit classic features of rickets.pharmacologic agents that compete for or inactivate the
common receptor, also known as the type I receptor, Despite the absence of vitamin D receptors, maintaining
knockout mice on a calcium-rich diet supplemented withfor PTH and PTH-related peptide (PTHrP). There is
evidence that certain peptide fragments derived from lactose to facilitate intestinal calcium absorption pre-
vents each of the aforementioned manifestations of vita-full-length 84-amino acid PTH, such as PTH(7-34), com-
pete with PTH(1-84) for binding to its receptor [77]. Such min D deficiency, including parathyroid gland hyperpla-
sia. Such findings suggest that the biologic actions ofinteractions might contribute to the skeletal resistance to
PTH that characterizes chronic renal failure, but direct vitamin D are not integral to the regulation of parathy-
roid gland hyperplasia. Rather, the maintenance of nor-evidence supporting this contention has yet to be pre-
sented. mal serum calcium levels, by actions mediated through
the CaSR, appears to be a more important determinantDr. Jeffrey Kraut (Division of Nephrology, West Los
Angeles VA Hospital, Los Angeles): Controversy sur- of parathyroid gland enlargement. The results predict
that treatment with vitamin D sterols will have littlerounds the role of metabolic acidosis in the pathogenesis
of renal osteodystrophy. Do you envision a role for con- impact on the course of parathyroid gland hyperplasia
in the setting of renal failure, whereas calcimimetictrolling acidosis, particularly during the interdialytic pe-
riod, in the management of renal bone disease, and, if agents are likely to impede parathyroid gland hyperpla-
sia. Recent studies indicate that calcimimetic agents areso, how aggressive should we be?
Dr. Goodman: Acidosis has adverse effects not only indeed capable of preventing parathyroid gland hyper-
plasia in subtotally nephrectomized rats [73].on mineralized tissues but also on bone cell activity, and
these changes can contribute to bone loss in patients Dr. Lee: Justin Silver’s group in Israel has proposed
another step in the regulation of PTH gene expressionwith chronic renal failure [78]. The use of bicarbonate
rather than acetate in hemodialysis solutions provides that involves the relative stability of PTH transcripts
[16]. Can you comment on these observations?better control of systemic acidosis and has beneficial
effects on bone in patients with end-stage renal disease Dr. Goodman: These investigators have shown that
hypocalcemia stabilizes the level of PTH mRNA and[78]. Ideally, the pre-dialysis plasma pH should be close
to 7.40 to minimize the long-term adverse impact of prolongs its half-life, whereas hypophosphatemia mark-
edly shortens the half-life of PTH mRNA. A corollaryuremic acidosis on renal bone disease, but few clinical
studies have addressed this issue. The issue that you effect of hyperphosphatemia to prolong the half-life of
PTH mRNA has not been reported, however, and thisraise might be particularly relevant for patients who use
sevelamer instead of calcium carbonate as a phosphate- point is of considerable interest with respect to hyper-
parathyroidism in chronic renal failure. The changes inbinding agent. The amount of alkali ingested daily is
much less in patients taking sevelamer, and modest re- PTH mRNA stability appear to be mediated by cytosolic
proteins that bind to uridine-rich elements in the 39 un-ductions in serum carbon dioxide levels have been re-
ported during treatment with this new phosphate-bind- translated region of PTH mRNA [80]. Such protein-
mRNA interactions might protect PTH mRNA from deg-ing agent.
Dr. Michael Bunnapradist (Division of Nephrology, radation by endonucleases, thereby stabilizing mRNA
levels and extending its half-life.Cedars Sinai Medical Center, Los Angeles): With these
wonderful new medications, what is the current role of
parathyroidectomy in dialysis and transplant patients? ACKNOWLEDGMENTS
Dr. Goodman: It has yet to be determined whether Work cited in this Forum was supported in part by USPHS grants
DK-52905, DK-35423, and RR-00865.the availability of additional vitamin D sterols or the
introduction of calcimimetic compounds can diminish
Reprint requests to Dr. William Goodman, Division of Nephrology,
the need for parathyroid surgery in either group of pa- 7-155 Factor Building, UCLA Medical Center, 10833 Le Conte Avenue,
Los Angeles, California 90095-1689, USA.tients. It is difficult, if not impossible, to reverse the
E-mail:wgoodman@ucla.eduprocess of parathyroid gland hyperplasia and to reduce
the size of the parathyroid glands once secondary hyper-
REFERENCESparathyroidism becomes established. Prevention rather
than treatment is probably more important. 1. Delmez JA, Slatopolsky E: Hyperphosphatemia: Its conse-
quences and treatment in patients with chronic renal disease. AmIn this regard, the findings of Demay and colleagues
J Kidney Dis 19:303–317, 1992
in mice homozygous for an inactivating mutation of the 2. Slatopolsky E, Delmez JA: Pathogenesis of secondary hyperpara-
thyroidism. Am J Kidney Dis 23:229–236, 1994gene encoding the vitamin D receptor are quite informa-
3. Pflanz S, Henderson IS, McElduff N, Jones NC: Calcium ace-tive [79]. These animals develop hypocalcemia and hypo-
tate versus calcium carbonate as phosphate-binding agents in
phosphatemia after weaning, serum PTH levels become chronic haemodialysis. Nephrol Dial Transplant 9:1121–1124, 1994
4. Mactier RA, Van Stone J, Cox A, et al: Calcium carbonate is anmarkedly elevated, and the parathyroid glands show a
Nephrology Forum: Treating secondary hyperparathyroidism1200
effective phosphate binder when dialysate calcium concentration absorption: A comparison of calcium carbonate and calcium ci-
trate. J Bone Miner Res 3:253–258, 1988is adjusted to control hypercalcemia. Clin Nephrol 28:222–226,
27. Schaefer K, Scheer J, Asmus G, et al: The treatment of uraemic1987
hyperphosphataemia with calcium acetate and calcium carbonate:5. Oettinger CW, Oliver JC, Macon EJ: The effects of calcium
A comparative study. Nephrol Dial Transplant 6:171–175, 1991carbonate as the sole phosphate binder in combination with low
28. Fournier A, Moriniere PH, Sebert JL, et al: Calcium carbonate,calcium dialysate and calcitriol therapy in chronic hemodialysis
an aluminum-free agent for control of hyperphosphatemia, hypo-patients. J Am Soc Nephrol 3:995–1001, 1992
calcemia and hyperparathyroidism in uremia. Kidney Int 29(Suppl6. Coburn JW, Salusky IB, Norris KC, et al: Oral and parenteral
18):S114–S119, 1986calcitriol for the management of end-stage renal disease. Contrib
29. Chertow GM, Burke SK, Lazarus JM, et al: Poly[allylamineNephrol 90:166–182, 1991
hydrochloride] (RenaGel): A noncalcemic phosphate binder for7. Block GA, Hulbert-Shearon TE, Levin NW, et al: Association
the treatment of hyperphosphatemia in chronic renal failure. Amof serum phosphorus and calcium 3 phosphorus product with
J Kidney Dis 29:66–71, 1997mortality risk in chronic hemodialysis patients: A national study.
30. Chertow GM, Dillon M, Burke SK, et al: A randomized trial ofAm J Kidney Dis 31:607–617, 1998
sevelamer hydrochloride (RenaGel) with and without supplemen-8. Goodman WG, Goldin J, Kuizon BD, et al: Coronary artery
tal calcium: Strategies for the control of hyperphosphatemia andcalcification in young adults with end-stage renal disease undergo-
hyperparathyroidism in hemodialysis patients. Clin Nephrol 51:18–ing dialysis. N Engl J Med 342:1478–1483, 2000
26, 19999. Kifor O, Moore FD Jr, Wang P, et al: Reduced immunostaining
31. Pei Y, Hercz G, Greenwood C, et al: Risk factors for renal osteo-for the extracellular Ca21-sensing receptor in primary and uremic
dystrophy: A multivariant analysis. J Bone Miner Res 10:149–156,secondary hyperparathyroidism. J Clin Endocrinol Metab 81:1598–
19951606, 1996
32. Sperschneider H, Gunther K, Marzoll I, et al: Calcium carbon-10. Korkor AB: Reduced binding of 3H-1,25-dihydroxyvitamin D in
ate (CaCO3): An efficient and safe phosphate binder in haemodial-the parathyroid glands of patients with renal failure. N Engl J Med
ysis patients? Nephrol Dial Transplant 8:530–534, 1993316:1573–1577, 1987
33. Hafner J, Keusch G, Wahl C, et al: Uremic small-artery disease11. Brown EM: Mechanisms underlying the regulation of parathyroid
with medial calcification and intimal hyperplasia (so-called calci-hormone secretion in vivo and in vitro. Curr Opin Nephrol Hyper-
phylaxis): A complication of chronic renal failure and benefit fromtens 2:541–551, 1993
parathyroidectomy. J Am Acad Dermatol 33:954–962, 199912. Okazaki T, Ando K, Igarashi T, et al: Conserved mechanism
34. Zacharias JM, Fontaine B, Fine A: Calcium use increases riskof negative gene regulation by extracellular calcium: Parathyroid
of calciphylaxis: A case-control study. Perit Dial Int 19:248–252,hormone gene versus atrial natriuretic polypeptide gene. J Clin
1999Invest 89:1268–1273, 1992
35. Burke TJ, Slatopolsky EA, Goldberg DI: RenaGel, a novel13. Almaden Y, Canalejo A, Hernandez A, et al: Direct effect of
calcium- and aluminum-free phosphate binder, inhibits phosphatephosphorus on parathyroid hormone secretion from whole para-
absorption in normal volunteers. Nephrol Dial Transplant 12:1640–thyroid glands in vitro. J Bone Miner Res 11:970–976, 1996 1644, 199714. Slatopolsky E, Finch J, Denda M, et al: Phosphorus restriction 36. Slatopolsky EA, Burke SK, Dillon MA: RenaGel, a nonab-
prevents parathyroid gland growth: High phosphorus directly stim- sorbed calcium- and aluminum-free phosphate binder, lowers se-
ulates PTH secretion in vitro. J Clin Invest 97:2534–2540, 1996 rum phosphorus and parathyroid hormone: The RenaGel Study
15. Denda M, Finch J, Slatopolsky E: Phosphorus accelerates the Group. Kidney Int 55:299–307, 1999
development of parathyroid hyperplasia and secondary hyperpara- 37. Chertow GM, Burke SK, Dillon MA, et al: Long-term effects
thyroidism in rats with renal failure. Am J Kidney Dis 28:596–602, of sevelamer hydrochloride on the calcium 3 phosphate product
1996 and lipid profile of haemodialysis patients. Nephrol Dial Transplant
16. Moallem E, Kilav R, Silver J, Naveh-Many T: RNA-protein 14:2709–2714, 1999
binding and post-transcriptional regulation of parathyroid hor- 38. Wilkes BM, Reiner D, Kern M, et al: Simultaneous lowering of
mone gene expression by calcium and phosphate. J Biol Chem serum phosphate and LDL-cholesterol by sevelamer hydrochloride
273:5253–5259, 1998 (RenaGel) in dialysis patients. Clin Nephrol 50:381–386, 1998
17. Coburn JW, Kopple JD, Brickman AS: Study of intestinal absorp- 39. Lindner A, Charra B, Sherrard DJ, et al: Accelerated atheroscle-
tion of calcium in patients with renal failure. Kidney Int 3:264–272, rosis in prolonged maintenance hemodialysis. N Engl J Med
1973 290:697–701, 1974
18. Okazaki T, Igarashi T, Kronenberg HM: 59-Flanking region of 40. Hergesell O, Ritz E: Phosphate binders on iron basis: A new
the parathyroid hormone gene mediates negative regulation by perspective? Kidney Int 73(Suppl 73):S42–S45, 1999
1,25-(OH)2 vitamin D3. J Biol Chem 263:2203–2208, 1988 41. Hutchison AJ: Calcitriol, lanthanum carbonate, and other new
19. Brown AJ, Dusso A, Lopez-Hilker S, et al: 1,25(OH)2D receptors phosphate binders in the management of renal osteodystrophy.
are decreased in parathyroid glands from chronically uremic dogs. Perit Dial Int 19(Suppl 2):S408–S412, 1999
Kidney Int 35:19–23, 1989 42. Sherrard DJ: Renal osteodystrophy. Semin Nephrol 6:56–67, 1986
20. Parfitt AM: The hyperparathyroidism of chronic renal failure: A 43. Hernandez D, Concepcion MT, Lorenzo V, et al: Adynamic bone
disorder of growth. Kidney Int 52:3–9, 1997 disease with negative aluminum staining in predialysis patients:
21. Lopez-Hilker S, Dusso A, Rapp N, et al: Phosphorus restriction Prevalence and evolution after maintenance dialysis. Nephrol Dial
reverses hyperparathyroidism in uremia independent of changes Transplant 9:517–523, 1994
in calcium and calcitriol. Am J Physiol 259:F432–F437, 1990 44. Schmitt CP, Huber D, Mehls O, et al: Altered instantaneous and
22. Rodriguez M, Felsenfeld AJ, Williams C, et al: The effect of calcium-modulated oscillatory PTH secretion patterns in patients
long-term intravenous calcitriol administration on parathyroid with secondary hyperparathyroidism. J Am Soc Nephrol 9:1832–
function in hemodialysis patients. J Am Soc Nephrol 2:1014–1020, 1844, 1998
1991 45. Brickman AS, Coburn JW, Norman AW: Action of 1,25-dihydrox-
23. Coburn JW, Norris KC, Nebeker HG: Osteomalacia and bone ycholecalciferol, a potent kidney-produced metabolite of vitamin
disease arising from aluminum. Semin Nephrol 6:68–89, 1986 D3, in uremic man. N Engl J Med 287:891–895, 1972
24. Sheikh MS, Maguire JA, Emmett M, et al: Reduction of dietary 46. Brickman AS, Coburn JW, Massry SG, et al: 1,25-Dihydroxyvita-
phosphorus absorption by phosphorus binders: A theoretical in min D3 in normal man and patients with renal failure. Ann Intern
vitro and in vivo study. J Clin Invest 83:66–73, 1989 Med 80:161–168, 1974
25. Slatopolsky E, Weerts C, Lopez-Hilker S, et al: Calcium carbon- 47. Smothers RL, Levine BS, Singer FR, et al: The relationship be-
ate is an effective phosphate binder in patients with chronic renal tween urinary calcium and calcium intake during treatment with
failure undergoing dialysis. N Engl J Med 315:157–161, 1986 calcitriol. Kidney Int 29:578–583, 1986
48. Slatopolsky E, Weerts C, Thielan J, et al: Marked suppression26. Harvey JA, Zobitz MM, Pak CYC: Dose dependency of calcium
Nephrology Forum: Treating secondary hyperparathyroidism 1201
of secondary hyperparathyroidism by intravenous administration to severe secondary hyperparathyroidism: Results of a multicenter
double-blinded, placebo-controlled study. Am J Kidney Dis 36:of 1,25-dihydroxycholecalciferol in uremic patients. J Clin Invest
74:2136–2143, 1984 562–565, 2000
65. Fukagawa M, Kitaoka M, Kaname S, et al: Suppression of parathy-49. Andress DL, Norris KC, Coburn JW, et al: Intravenous calcitriol
in the treatment of refractory osteitis fibrosa of chronic renal fail- roid gland hyperplasia by 1,25(OH)2D3 pulse therapy. N Engl J
Med 315:421–422, 1990ure. N Engl J Med 321:274–279, 1989
50. Salusky IB, Goodman WG, Horst R, et al: Pharmakokinetics of 66. Nemeth EF: Calcium receptors as novel drug targets, in Principles
in Bone Biology, edited by Bilezikian JP, Raisz LG, Rodan GA,calcitriol in CAPD/CCPD patients. Am J Kidney Dis 16:126–132,
1990 New York, Academic Press, 1996, pp 1019–1035
67. Wada M, Ishii H, Furuya Y, et al: NPS R-568 halts or reverses51. Quarles LD, Yohay DA, Carroll BA, et al: Prospective trial of
osteitis fibrosa in uremic rats. Kidney Int 53:448–453, 1998pulse oral versus intravenous calcitriol treatment of hyperparathy-
68. Nemeth EF: Ca12 receptor-dependent regulation of cellular func-roidism in ESRD. Kidney Int 45:1710–1721, 1994
tions. News Physiol Sci 10:1–5, 199552. Brown AJ, Dusso A, Slatopolsky E: Selective vitamin D analogs
69. Okazaki T, Zajac JD, Igarashi T, et al: Negative regulatory ele-and their therapeutic applications. Semin Nephrol 14:156–174, 1994
ments in the human parathyroid hormone gene. J Biol Chem53. Brown AJ, Ritter CR, Finch JL, et al: The noncalcemic analogue
266:21903–21910, 1991of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone
70. Nemeth EF, Steffey ME, Hammerland LG, et al: Calcimimeticssynthesis and secretion. J Clin Invest 84:728–732, 1989
with potent and selective activity on the parathyroid calcium recep-54. Monier-Faugere MC, Geng Z, Friedler RM, et al: 22-Oxacalci-
tor. Proc Natl Acad Sci USA 95:4040–4045, 1998triol suppresses secondary hyperparathyroidism without inducing
71. Fox J, Lowe SH, Conklin RL, et al: The calcimimetic NPS R-568low bone turnover in dogs with renal failure. Kidney Int 55:821–832,
decreases plasma PTH in rats with mild and severe renal or dietary1999
secondary hyperparathyroidism. Endocrinology 10:97–103, 199955. Kamimura S, Gallieni M, Kubodera N, et al: Differential catabo-
72. Hebert S: Extracellular calcium-sensing receptor: Implications forlism of 22-oxacalcitriol and 1,25-dihydroxyvitamin D3 by normal
calcium and magnesium handling in the kidney. Kidney Int 50:2129–human peripheral monocytes. Endocrinology 133:2719–2723, 1993
2139, 199656. Slatopolsky E, Finch J, Ritter C, et al: A new analog of calcitriol,
73. Wada M, Furuya Y, Sakiyama J, et al: The calcimimetic compound19-nor-1,25-(OH)2D2, suppresses parathyroid hormone secretion NPS R-568 suppresses parathyroid cell proliferation in rats within uremic rats in the absence of hypercalcemia. Am J Kidney Dis
renal insufficiency: Control of parathyroid cell growth via a calcium26:852–860, 1995
receptor. J Clin Invest 100:2977–2983, 199757. Brown AJ: Vitamin D analogues. Am J Kidney Dis 32(Suppl
74. Antonsen JE, Sherrard DJ, Andress DL: A calcimimetic agent2):S25–S39, 1998
acutely suppresses parathyroid hormone levels in patients with58. Takahashi F, Finch JL, Denda M, et al: A new analog of 1,25- chronic renal failure. Kidney Int 53:223–227, 1998(OH)2D3, 19-nor-1, 25-(OH)2D2, suppresses serum PTH and para- 75. Goodman WG, Frazao JM, Turner A, et al: Use of a calcimimeticthyroid gland growth in uremic rats without elevation of intestinal agent to lower plasma parathyroid hormone levels in hemodialysis
vitamin D receptor content. Am J Kidney Dis 30:105–112, 1997 patients with secondary hyperparathyroidism. Kidney Int 58:436–
59. Martin KJ, Gonzalez EA, Gellens M, et al: 19-Nor-1-a-25-dihy- 445, 2000
droxyvitamin D2 (paricalcitol) safely and effectively reduces the 76. Brown AJ, Finch J, Grieff M: The mechanism for the disparate
levels of intact parathyroid hormone in patients on hemodialysis. actions of calcitriol and 22-oxacalcitriol in the intestine. Endocri-
J Am Soc Nephrol 9:1427–1432, 1998 nology 133:1158–1164, 1993
60. Sjo¨den G, Lindgren JU, DeLuca HF: Antirachitic activity of 1a- 77. Ju¨ppner H, Shipani E, Bringhurst FR, et al: The extracellular
hydroxyergocalciferol and 1a-hydroxcholecalciferol. J Nutr 114: animo-terminal region of the parathyroid hormone (PTH)/PTH-
2043–2046, 1984 related peptide receptor determines the binding affinity for car-
61. Sjo¨den G, Smith C, Lindgren JU, et al: 1a-hydroxyvitamin D2 is boxyl-terminal fragments of PTH-(1-34). Endocrinology 134:879–
less toxic than 1a-hydroxvitamin D3 in the rat. Proc Soc Exp Biol 884, 1994
Med 178:432–436, 1985 78. Lefebvre A, de Vernejoul MC, Gueris J, et al: Optimal correction
62. Gallagher JC, Bishop CW, Knutson JC, et al: Effects of increas- of acidosis changes progression of dialysis osteodystrophy. Kidney
ing doses of 1a-hydroxyvitamin D2 on calcium homeostasis in post- Int 36:1112–1118, 1989
menopausal osteopenic women. J Bone Miner Res 9:607–614, 1994 79. Li YC, Amling M, Pirro AE, et al: Normalization of mineral
63. Tan AU Jr, Levine BS, Mazess RB, et al: Effective suppression ion homeostasis by dietary means prevents hyperparathyroidism,
of parathyroid hormone by 1 alpha-hydroxy-vitamin D2 in hemodi- rickets, and osteomalacia, but not alopecia in vitamin D receptor-
alysis patients with moderate to severe secondary hyperparathy- ablated mice. Endocrinology 139:4391–4396, 1998
roidism. Kidney Int 51:317–323, 1997 80. Yalcindag C, Silver J, Naveh-Many T: A mechanism of increased
64. Frazao JM, Elangovan L, Chesney RW, et al: One-alpha-hydroxy- parathyroid hormone mRNA in experimental uremia: Roles of
vitamin D2 (doxercalciferol) effectively and safely suppresses intact protein RNA binding in RNA degradation. J Am Soc Nephrol
10:2562–2568, 1999parathyroid hormone levels in hemodialysis patients with moderate
